Sprint Bioscience
1.93 SEK
+2.39 %
Less than 1K followers
SPRINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Sprint Bioscience
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.8 | 16.3 | 65.6 | 14.1 | 13.9 | 5.2 | 133.9 | 167.2 |
| EBITDA | -5.1 | -4.9 | -18.7 | -4.7 | -7.1 | -8.1 | 118.3 | 98.4 |
| EBIT | -5.4 | -4.9 | -19.7 | -5.0 | -6.8 | -8.4 | 117.5 | 97.3 |
| EBIT-% | -36.4 % | -30.2 % | -30.0 % | -35.5 % | -49.0 % | -160.3 % | 87.8 % | 58.2 % |
| Profit before taxes | -5.2 | -3.6 | -18.3 | -5.6 | -7.4 | -8.4 | 113.2 | 91.7 |
| Net income | -5.2 | -3.6 | -18.3 | -5.6 | -7.4 | -8.4 | 113.2 | 91.7 |